文献速递肝胆胰外科

机器人辅助肝门部胆管癌根治术的临床疗效分析

[Analysis of the clinical efficacy of robot-assisted radical resection for hilar cholangiocarcinoma].
PubMed 文献 · Zhonghua Wai Ke Za Zhi · 2025-01-01

本研究回顾性分析29例接受机器人辅助肝门部胆管癌根治术患者的临床资料,R0切除率为93.1%,无中转开腹,Clavien-Dindo Ⅱ级以上并发症发生率为24.1%,术后90天病死率为3.4%。Cox多因素回归分析显示R0切除是术后1年生存状态的独立预后因素。

要点

  • 机器人辅助肝门部胆管癌根治术可行,R0切除率达93.1%。
  • Ⅱ级以上并发症发生率为24.1%,术后90天病死率为3.4%。
  • R0切除是术后1年生存状态的独立预后因素。

核心结论

  • 机器人辅助肝门部胆管癌根治术是可行的且效果较好。

研究设计与样本

  • 回顾性病例系列研究,纳入2021年7月至2025年2月于哈尔滨医科大学附属第一医院接受机器人辅助肝门部胆管癌根治术的29例患者。

主要发现

  • 29例均顺利完成手术,R0切除率93.1%(27/29),无中转开腹。
  • 手术时间295.0(87.5)min,术中出血量100.0(150.0)ml,术中输血率20.1%(6/29),淋巴结清扫数目10.0(7.0)枚。
  • Clavien-Dindo Ⅱ级以上并发症发生率24.1%(7/29),包括消化道出血伴反复高热3例、胃排空延迟1例、胆瘘1例、低白蛋白血症5例。
  • 术后90 d病死率3.4%(1/29);随访时间15.0(12.0)个月,无瘤生存率65.5%(19/29),总体生存率68.9%(20/29)。
  • Cox多因素回归分析显示R0切除是术后1年生存状态的独立预后因素(P<0.05)。

关键数值与推荐

  • R0切除率93.1%(27/29)。
  • Clavien-Dindo Ⅱ级以上并发症发生率24.1%(7/29)。
  • 术后90 d病死率3.4%(1/29)。
  • 无瘤生存率65.5%(19/29),总体生存率68.9%(20/29)。

临床怎么用

  • 机器人辅助手术可作为肝门部胆管癌根治术的可选术式,需关注R0切除以改善预后。

局限性

  • 本研究为回顾性病例系列研究,样本量有限(29例),随访时间较短。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To investigate the feasibility and therapeutic efficacy of robot-assisted radical resection for hilar cholangiocarcinoma. Methods: This is a retrospective case series study. The clinical data of 29 patients who underwent robot-assisted radical resection for hilar cholangiocarcinoma at the Department of Minimally Invasive Hepatic Surgery,the First Affiliated Hospital of Harbin Medical University from July 2021 to February 2025 were retrospectively collected. There were 16 males and 13 females, aged (M(IQR)) 68.0 (10.0) years (range:36 to 78 years), and body mass index (24.0±2.9) kg/m2 (range:17.5 to 29.1 kg/m2). Bismuth-Corlette classification: 12 cases type Ⅰ, 4 cases type Ⅱ, 6 cases type Ⅲb, and 7 cases type Ⅳ. Preoperative CA19-9 was 161.7(320.9) U/ml (range:7.1 to 1 000.0 U/ml), and carcinoembryonic antigen was 2.8(2.1)μg/L (range:0.3 to 203.1 μg/L). Preoperative total bilirubin was 134.2 (348.9) μmol/L (range:10.4 to 557.9 μmol/L), direct bilirubin was 90.8 (264.1) μmol/L (range:2.5 to 418.7 μmol/L), ALT was 136.4 (134.8) U/L (range:13.0 to 569.9 U/L), AST was 122.2 (119.9) U/L (range:16.0 to 384.0 U/L), and albumin was (34.5±6.3) g/L (range:21.7 to 41.3 g/L). Comparison of quantitative data at different time points using paired t-test or Mann-Whitney U test. Cox univariate analysis was performed for the relevant variables, and Cox multivariate regression analysis was used to screen the independent prognostic factors of patients after robot-assisted radical resection for hilar cholangiocarcinoma. Results: All the 29 patients successfully underwent robot-assisted radical resection of hilar cholangiocarcinoma, and the R0 resection rate was 93.1% (27/29) without conversion to laparotomy. The operation time was 295.0 (87.5) minutes (range:195 to 590 minutes), the intraoperative blood loss was 100.0 (150.0) ml (range:20 to 1 000 ml), the intraoperative blood transfusion rate was 20.1% (6/29), the number of lymph nodes dissected was 10.0 (7.0) pieces (range: 6 to 18 pieces), the first postoperative deflatus time was 3.0 (1.0) days (range:2 to 4 days), The oral feeding time was 5.0 (1.0) days (range: 4 to 7 days), the drainage tube removal time was 8.0 (2.0) days (range: 6 to 26 days), and the postoperative hospital stay time was 10.0 (6.0) days (range:7 to 27 days). The incidence of complications above grade Ⅱ of the Clavien-Dindo complication grading system was 24.1% (7/29), including 3 cases of gastrointestinal bleeding with recurrent high fever, 1 case of delayed gastric emptying, 1 case of bile leakage, and 5 cases of hypoalbuminemia. The total bilirubin was 42.8 (66.8) μmol/L (range:6.8 to 195.9 μmol/L), direct bilirubin was 28.1 (38.5) μmol/L (range:4.3 to 88.6 μmol/L), ALT was 55.8 (56.0) U/L (range:9.9 to 207.1 U/L), AST was 33.9 (17.9) U/L (range:10.6 to 122.7 U/L), and albumin was (32.1±3.8) g/L (range:22.8 to 37.7 g/L), the levels of transaminase and bilirubin in the postoperative liver function indexes were significantly improved compared with those before operation, and the differences were statistically significant (all P<0.05). The mortality rate of patients without perioperative death was 3.4% (1/29) at 90 days after surgery. The results of Cox multivariate regression analysis showed that R0 resection was an independent prognostic factor for survival at 1 year after surgery (P<0.05). The follow-up time was 15.0 (12.0) months (range:6 to 30 months), 1 of the 29 patients died of intra-abdominal infection 1 week after discharge, and the remaining 28 patients were completely followed up, of which 20 patients had no recurrence and metastasis during the follow-up period, and the tumor-free survival was 15.0 (12.0) months (range:6 to 30 months), the tumor-free survival rate was 65.5% (19/29), the overall survival rate was 68.9% (20/29), and 8 patients with postoperative recurrence and metastasis. One patient with liver metastasis survived after reoperation, and one patient underwent postoperative chemoradiotherapy and died due to recurrence. There were 8 deaths during the follow-up, of which 7 died due to tumor recurrence and metastasis, and 1 died due to previous underlying diseases. Conclusion: Robot-assisted radical resection for hilar cholangiocarcinoma is feasible and effective. 目的: 探讨机器人辅助肝门部胆管癌根治术的可行性和疗效。 方法: 本研究为回顾性病例系列研究。回顾性收集2021年7月至2025年2月于哈尔滨医科大学附属第一医院接受机器人辅助肝门部胆管癌根治术治疗的29例患者的临床资料。男性16例,女性13例,年龄[M(IQR)]68.0(10.0)岁(范围:36~78岁),体重指数(24.0±2.9)kg/m2(范围:17.5~29.1 kg/m2)。Bismuth-Corlette分型:Ⅰ型12例,Ⅱ型4例,Ⅲb型6例,Ⅳ型7例。术前CA19-9为161.7(320.9)U/ml(范围:7.1~1 000.0 U/ml),癌胚抗原为2.8(2.1)μg/L(范围:0.3~203.1 μg/L)。术前总胆红素134.2(348.9)μmol/L(范围:10.4~557.9 μmol/L),直接胆红素90.8(264.1)μmol/L(范围:2.5~418.7 μmol/L),丙氨酸氨基转移酶(ALT)136.4(134.8)U/L(范围:13.0~569.9 U/L),天冬氨酸氨基转移酶(AST)122.2(119.9)U/L(范围:16.0~384.0 U/L),白蛋白(34.5±6.3)g/L(范围:21.7~41.3 g/L)。不同时间点定量资料的比较使用配对t检验或Mann-Whitney U检验。通过Cox单因素分析和多因素回归分析筛选机器人辅助肝门部胆管癌根治术后患者的独立预后因素。 结果: 29例患者均顺利完成机器人辅助肝门部胆管癌根治术,R0切除率为93.1%(27/29),无中转开腹。手术时间295.0(87.5)min(范围:195~590 min)、术中出血量100.0(150.0)ml(范围:20~1 000 ml)、术中输血率为20.1%(6/29)、淋巴结清扫数目10.0(7.0)枚(范围:6~18枚)、术后首次排气时间3.0(1.0)d(范围:2~4 d)、经口进食时间为5.0(1.0)d(范围:4~7 d)、引流管拔除时间8.0(2.0)d(范围:6~26 d)、术后住院时间10.0(6.0)d(范围:7~27 d)。Clavien-Dindo并发症分级系统Ⅱ级以上并发症发生率24.1%(7/29),包括消化道出血伴反复高热3例、术后胃排空延迟1例、胆瘘1例、低白蛋白血症5例。术后总胆红素42.8(66.8)μmol/L(范围:6.8~195.9 μmol/L)、直接胆红素28.1(38.5)μmol/L(范围:4.3~88.6 μmol/L)、ALT 55.8(56.0)U/L(范围:9.9~207.1 U/L)、AST 33.9(17.9)U/L(范围:10.6~122.7 U/L)、白蛋白(32.1±3.8)g/L(范围:22.8~37.7 g/L),术后肝功能指标中转氨酶及胆红素水平较术前明显改善,差异均有统计学意义(P值均<0.05)。无围手术期死亡患者,术后90 d病死率为3.4%(1/29)。Cox多因素回归分析结果显示,是否R0切除为术后1年生存状态的独立预后因素(P值<0.05)。29例患者中1例患者出院后1周因腹腔感染死亡,其余28例均得到完整随访,随访时间15.0(12.0)个月(范围:6~30个月),其中20例随访期间无复发及转移,无瘤生存期15.0(12.0)个月(范围:6~30个月),无瘤生存率为65.5%(19/29),总体生存率为68.9%(20/29);术后复发及转移患者8例,其中1例发生肝转移的患者接受再次手术治疗,1例行术后接受放化疗后因复发死亡。随访中死亡8例,其中7例因肿瘤复发及转移死亡,1例因既往基础疾病死亡。 结论: 机器人辅助手术治疗肝门部胆管癌根治术是可行的且效果较好。.

来源:Zhonghua Wai Ke Za Zhi,查看原文。版权归原作者所有。

引用

  1. Bao DL, Yang GC, Li ZY, et al. [Analysis of the clinical efficacy of robot-assisted radical resection for hilar cholangiocarcinoma]. Zhonghua Wai Ke Za Zhi. 2025. PMID: 40258795. doi:10.3760/cma.j.cn112139-20250114-00027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。